This study used a validated algorithm to map EQ-5D utilities from Migraine-Specific Quality of Life questionnaire version 2.1 (MSQv2) scores collected during 64 weeks of follow-up in study BHV3000-305 of rimegepant as a preventive migraine treatment in adult patients with 4–18 monthly migraine days (MMDs).

Rimegepant 75 mg every other day was associated with greater improvement in MMDs and EQ-5D utilities compared to placebo during the 12-week double-blind treatment (DBT) phase. The MSQv2 and mapped EQ-5D measures of participants originally randomized to the placebo arm caught up to the rimegepant arm during the first 12 weeks of the open-label extension study (OLE), demonstrating rapid onset of effect.

There were further improvements in MSQv2 and mapped health state utility values in both trial arms over the 52-week OLE phase, where all patients were asked to take rimegepant 75 mg every other day (EOD).

These findings can inform economic evaluations of rimegepant, where health state utility measures are required to compare treatment efficacy against standard of care and other novel therapies.